Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Micromet reports on symposium on EpCAM biology and clinical application
February 27th, 2007
Micromet, Inc. (MITI) reports in the British Journal of Cancer on proceedings from an international symposium on EpCAM, a target antigen the company has selected for two drug candidates. One is the human antibody adecatumumab (MT201), which has completed two phase IIa trials. The other one is MT110, a BiTE molecule, which is in formal preclinical development. EpCAM is one of the most frequently and intensely expressed tumor-associated antigens known. One highlight of the symposium was very recent data from the laboratory of Olivier Gires, University of Munich, showing that overexpressed EpCAM is a highly potent oncogenic signaling molecule in...
Source: Cancer Weekly (2007-02-27)
|
